American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 | Latest News RSS feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 - Latest News


American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert ...

INGELHEIM, Germany & INDIANAPOLIS, Ind.--(BUSINESS WIRE)--A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inh... read more

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 ...

INGELHEIM, Germany & INDIANAPOLIS, Ind. — A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the ... read more

Looking for another news?


Cardiology association recommends Lilly's Jardiance for lowering CV risk in type 2 diabetics

Eli Lilly (LLY-0.3%) and alliance partner Boehringer Ingelheim announce that the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for ... read more


ACC recommends drugs for type 2 Diabetes

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway A n... read more

ACC offers guidance on using diabetes drugs for CV event reduction

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients w... read more

ACC Consensus on New Diabetes Drugs to Reduce CV Outcomes

The American College of Cardiology has issued an Expert Consensus Decision Pathway aimed at educating cardiologists on the use of two major new classes of diabetes drugs — sodium-glucose cotransporter ... read more

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

“There is an urgent need for treatment options that can improve cardiovascular-related outcomes in people with type 2 diabetes and peripheral artery disease ... American College of Cardiology (ACC) re... read more

LLY Apr 2015 72.500 call

PR Newswire•13 hours ago American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Conse... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults ... the American College of Cardiology (ACC) rec... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us